Mallinckrodt Gestione

Gestione criteri di controllo 0/4

Mallinckrodt Il CEO è Siggi Olafsson, nominato in Jun2022, e ha un mandato di 1.42 anni. la retribuzione annua totale è $ 6.97M, composta da 8.2% di stipendio e 91.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.3% delle azioni della società, per un valore di $ 2.78K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.3 anni e 1.4 anni.

Informazioni chiave

Siggi Olafsson

Amministratore delegato

US$7.0m

Compenso totale

Percentuale dello stipendio del CEO	8.2%
Mandato del CEO	1.4yrs
Proprietà del CEO	0.3%
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	1.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Siggi Olafsson rispetto agli utili di Mallinckrodt?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 29 2023	n/a	n/a	-US$3b
Jun 30 2023	n/a	n/a	-US$2b
Mar 31 2023	n/a	n/a	-US$1b

Compensazione vs Mercato: La retribuzione totale di Siggi ($USD 6.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 650.80K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Siggi con le performance aziendali.

AMMINISTRATORE DELEGATO

Siggi Olafsson (54 yo)

1.4yrs

Mandato

US$6,965,770

Compensazione

Mr. Sigurdur Oli Olafsson, also known as Siggi, Ph D., serves as President and Chief Executive Officer and Director at Mallinckrodt plc since June 25, 2022. He had been an Executive officer since May 2022...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Sigurdur Olafsson	CEO, President & Director	1.4yrs	US$6.97m	0.30% $ 2.8k
Bryan Reasons	Executive VP & CFO	4.7yrs	US$3.82m	0.16% $ 1.5k
Mark Tyndall	Executive VP	1.3yrs	US$3.96m	0.10% $ 961.9
Henriette Nielsen	Executive VP & Chief Transformation Officer	1.3yrs	US$2.46m	0.091% $ 855.9
Stephen Welch	Executive VP & Head of Specialty Generics	no data	US$2.24m	0.057% $ 536.0
Peter Richardson	Executive VP & Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Kassie Harrold	Executive VP & Chief Compliance Officer	2.8yrs	Nessun dato	0.052% $ 487.9
Daniel Speciale	Senior VP of Finance & CFO of Specialty Generics	less than a year	Nessun dato	Nessun dato
Jason Goodson	Executive VP & Chief Strategy and Restructuring Officer	less than a year	Nessun dato	0.061% $ 567.2
Lisa French	Executive VP & Chief Commercial Officer	1.1yrs	Nessun dato	0.11% $ 1.0k
John Einwalter	VP & Treasurer	no data	Nessun dato	Nessun dato
David Keenan	VP of Global External Manufacturing & MD of Mallinckrodt Pharmaceuticals	9.8yrs	Nessun dato	Nessun dato

1.3yrs

Durata media

50.5yo

Età media

Gestione esperta: Il team dirigenziale di MNKT.Q non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Sigurdur Olafsson	CEO, President & Director	1.4yrs	US$6.97m	0.30% $ 2.8k
Paul Bisaro	Independent Chairman of the Board	1.4yrs	US$723.10k	0.0098% $ 91.7
James Sulat	Independent Director	1.4yrs	US$628.37k	0.30% $ 2.8k
Woodrow Myers	Independent Director	1.4yrs	US$611.28k	0.075% $ 698.9
John Vierling	Member of Scientific Advisory Council	no data	Nessun dato	Nessun dato
Neal Goldman	Independent Director	1.4yrs	US$626.74k	0.075% $ 698.9
Daniel Celentano	Independent Director	1.4yrs	US$615.92k	0.075% $ 698.9
Ulrich von Andrian-Werburg	Member of Scientific Advisory Council	5.4yrs	Nessun dato	Nessun dato
Karen Ling	Independent Director	1.3yrs	US$451.22k	0.075% $ 698.9
Riad El-Dada	Independent Director	1.4yrs	US$607.47k	0.075% $ 698.9
Jörg Gerlach	Member of Scientific Advisory Council	5.4yrs	Nessun dato	Nessun dato
Rashmin Savani	Member of Scientific Advisory Council	5.4yrs	Nessun dato	Nessun dato

1.4yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di MNKT.Q non è considerato esperto (durata media del mandato 1.4 anni), il che suggerisce un nuovo consiglio.

Mallinckrodt Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer

Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board

Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors

Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022

Recent updates

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024

Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024

Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector

CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.

Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024

Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress

Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024

Mallinckrodt plc, Annual General Meeting, May 09, 2024

Mallinckrodt plc Provides Earnings Guidance for the Year 2024

Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands

Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder

Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting

Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection)

Mallinckrodt Reportedly Considers Sale of Opioid Business

Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)

Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index

NYSE American to Commence Delisting Proceedings Against Mallinckrodt

Mallinckrodt plc Filed for Bankruptcy

Mallinckrodt plc is Heading Towards Bankruptcy

Mallinckrodt plc Contemplates Bankruptcy

Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023

Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc

Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome

Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients

Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023

Mallinckrodt plc Provides Earnings Guidance for the Year 2023

Mallinckrodt plc to Report Q4, 2022 Results on Feb 28, 2023

Mallinckrodt plc Presents New TERLIVAZ® for Injection Data on Hepatorenal Syndrome Reversal at the Society of Critical Care Medicine 2023 Critical Care Congress

Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer

Mallinckrodt plc Provides Financial Guidance for the Full-Year 2022

Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (Hrs) At the American Society of Nephrology (Asn) Kidney Week 2022 Scientific Meeting

Mallinckrodt plc NEW SHS Deleted from OTC Equity

Mallinckrodt plc to Report Q3, 2022 Results on Nov 08, 2022

Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board

Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors

Mallinckrodt plc Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System

Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022

Mallinckrodt Receives U.S. FDA Approval for Terlivaz (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS)

Mallinckrodt plc, Annual General Meeting, Sep 29, 2022

Mallinckrodt plc Provides Update on Executive Committee

Mallinckrodt plc Provides Revenue Guidance for the Full Year of 2022

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media